SCHEMBL71983

SCHEMBL71983

Cn1c(C(=O)O)ccc1C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.48
KDM4E B2RXH2 6/20 0.44
HSD17B10 Q99714 5/20 0.44
ALDH1A1 P00352 4/20 0.44
HPGD P15428 3/20 0.44
GPR35 Q9HC97 1/20 0.43
POLB P06746 1/20 0.42
APEX1 P27695 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
GFER P55789 1/20 0.41
GRN P28799 1/20 0.39
SORT1 Q99523 1/20 0.39
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC8 Q9BY41 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5172834 0.85 MCL1 (0.42) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL1663159 0.85 NAMPT (0.44) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL7860405 0.84 NPC1 (0.47) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL5172868 0.83 MCL1 (0.41) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL3277119 0.83 MCL1 (0.41) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL1529724 0.83 MCL1 (0.46) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL10937459 0.82 HDAC10 (0.53) MCL1HSD17B10ALDH1A1POLBTDP1
SCHEMBL12740590 0.81 MCL1 (0.40) MCL1KDM4EHSD17B10ALDH1A1HPGD
SCHEMBL10936763 0.79 CXCL8 (0.64) MCL1ALDH1A1HPGDSMN1; SMN2CXCL8
SCHEMBL3494614 0.79 HDAC10 (0.40) MCL1KDM4EHSD17B10ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1778299-A4 METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INT BV (NL) 2009-08-26 EP claimed
EP-1778299-A2 METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2007-05-02 EP claimed
WO-2006096207-A2 METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2006-09-14 WO claimed
US-20050147555-A1 Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same BRACCO SUISSE SA (CH) 2005-07-07 US claimed
US-12637563-B2 Modifiers for polyesters that improve viscosity in melt KANEKA AMERICAS HOLDING, INC. (US) 2026-05-26 US disclosed
US-20260015444-A1 MODIFIERS FOR POLYESTERS THAT IMPROVE VISCOSITY IN MELT KANEKA AMERICAS HOLDING, INC. (US) 2026-01-15 US disclosed
WO-2024010749-A1 MODIFIERS FOR POLYESTERS THAT IMPROVE VISCOSITY IN MELT KANEKA AMERICAS HOLDING, INC. (US) 2024-01-11 WO disclosed
US-20230062748-A1 MODIFIERS FOR POLYESTERS THAT IMPROVE VISCOSITY IN MELT KANEKA AMERICAS HOLDING, INC. (US) 2023-03-02 US disclosed
CN-115485313-A Improver for polyesters for improving melt viscosity 钟化美洲控股公司 2022-12-16 CN disclosed
WO-2021159009-A1 MODIFIERS FOR POLYESTERS THAT IMPROVE VISCOSITY IN MELT KANEKA AMERICAS HOLDING, INC. (US) 2021-08-12 WO disclosed
CN-109415457-B Method for preparing functionalized polymers 株式会社普利司通 2021-05-25 CN disclosed
EP-3099692-B9 BIFUNCTIONAL CYTOTOXIC AGENTS PFIZER (US) 2019-11-13 EP disclosed
US-20070191349-A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases SPIROGEN LIMITED (GB) 2007-08-16 US disclosed
US-20070191349-A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases SPIROGEN LIMITED (GB) 2007-08-16 US disclosed
EP-1778299-A2 METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2007-05-02 EP disclosed
EP-1720880-A1 C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEREOF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES Spirogen Limited (GB) 2006-11-15 EP disclosed
WO-2006096207-A2 METHODS FOR PREPARING MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS BRACCO INTERNATIONAL B.V. (NL) 2006-09-14 WO disclosed
WO-2006095234-A2 INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS BRACCO IMAGING S.P.A. (IT) 2006-09-14 WO disclosed
WO-2005085250-A1 C8, C8' LINKED 5-OXO-1,2,3,11A-TETRAHYDRO-5H-PYRROLO[2,1-C][1,4]BENZODIAZEPINE DIMERS WITH 1H-PYRROLE-DICARBOXYLIC ACID AMIDE LINKERS AND OLIGOMERIC ANALOGS THEROF AS WELL AS RELATED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SPIROGEN LIMITED (GB) 2005-09-15 WO disclosed
US-20050147555-A1 Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same BRACCO SUISSE SA (CH) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191349-A1 C8, c8' linked 5-oxo-1,2,3,11a-tetrahydro-5h-pyrrolo[2,1-c][1,4] benzodiazepine dimers with 1h-pyrrole-dicarboxylic acid amide linkers and oligomeric analogs therof as well as related compounds for the treatment of proliferative diseases TSPO, GABRD, BCOR MCL1 1329/4885KDM4E 3095/4885HSD17B10 2019/4885
US-20050147555-A1 Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same LDHB, FPGS, MTHFD2 MCL1 1653/4885KDM4E 2964/4885HSD17B10 718/4885
US-12637563-B2 Modifiers for polyesters that improve viscosity in melt CRYAA, INCENP, CRYAB MCL1 2610/4885KDM4E 2052/4885HSD17B10 384/4885
US-20260015444-A1 MODIFIERS FOR POLYESTERS THAT IMPROVE VISCOSITY IN MELT CRYAA, CRYAB, RCC1 MCL1 2965/4885KDM4E 1991/4885HSD17B10 1930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.